Home / Clinics Supported / Peptide Therapy
Open a Peptide Therapy Clinic Built on What Is Lawful to Compound Today.
Peptide searches have passed Ozempic in U.S. volume, 10.1 million a month. But BPC-157, TB-500, ipamorelin and most of the compounds driving that demand are not on the 503A Bulks List, which means no pharmacy can lawfully compound them right now. Knowing which is which is the whole business. ACG builds the version of this clinic that is still open in three years.
Book a Strategy CallThe Demand Is Real.
Most of the Menu Is Not Legal.
Peptide-related searches reached 10.1 million monthly in the U.S. as of January 2026. "Cost of peptide therapy" is up 300% year over year. Peptide searches have now surpassed Ozempic in U.S. search volume. The global peptide therapeutics market reached $163.98 billion in 2026 and is projected to reach $294.58 billion by 2033.
That is the opportunity. Here is the trap. The compounds generating most of that search volume, BPC-157 above all, cannot lawfully be compounded by a 503A pharmacy today. Operators are opening clinics around them anyway, because a supplier said it was fine, or because an advisory committee voted favorably and someone read that as approval.
A clinic that has already built protocols, pricing, and marketing around a compound that never gets listed has not just wasted the work. It has created a written record of intent.
Source: SEMrush, January 2026. Local demand varies by market.
Stop Asking If It Is Category 2.
Most operators, and a surprising number of consultants, still use Category 2 as their legality test. That model is now wrong, and wrong in a way that produces confident bad advice.
In April 2026 the FDA removed twelve peptides from Category 2. Removal from Category 2 is not approval. It moves a substance out of the significant-safety-risk bucket and into a queue awaiting formal evaluation. Five others left Category 2 back in September 2024 for a much duller reason: the people who nominated them withdrew the nominations.
Neither event created permission to compound anything.
A 503A pharmacy may compound from a bulk substance only if it is on the 503A Bulks List, is a component of an FDA-approved drug, or has a USP or NF monograph. That is the test. For most research peptides, the answer today is still no.
"Is it still Category 2?" This tells you almost nothing about whether a pharmacy can lawfully make it.
"Is it on the 503A Bulks List yet?" A yes is permission. Anything else is not.
In July 2026 an FDA advisory committee recommended six of seven reviewed peptides for the Bulks List, against FDA staff recommendation. The votes are non-binding. The FDA is not obligated to follow them, and rulemaking is expected to take 12 months or longer.
Is there an FDA-approved product. May a pharmacy compound it. Is it sold Research Use Only. Operators collapse these into one question and reach the wrong answer.
Where Each Compound Actually Stands
This is the table every operator asks for and almost nobody publishes. It reflects ACG's understanding of the current federal position. It is not legal advice, and it has a short shelf life.
| Agent | Status | Basis and conditions |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | FDA Approved | Prescribe the approved product. Off-label use is permitted with documentation. |
| Tirzepatide (Mounjaro, Zepbound) | FDA Approved | Prescribe the approved product. See our metabolic and weight loss clinic model for the full GLP-1 build. |
| Liraglutide (Saxenda, Victoza) | FDA Approved | Approved product. Its compounding position differs from the other two, see the conditional rows below. |
| Tesamorelin (Egrifta) | FDA Approved | Approved for HIV-associated lipodystrophy. Metabolic and NAFLD use is off-label and requires a signed off-label consent. |
| Bremelanotide, PT-141 (Vyleesi) | FDA Approved | Approved finished product. Pairs with a sexual wellness service line. |
| Endocrine and diagnostic peptides | FDA Approved | Human insulin, oxytocin, vasopressin, desmopressin, octreotide, teriparatide (Forteo), leuprolide (Lupron), cosyntropin. |
| Sermorelin | Conditional | Compoundable on the strength of its prior approval standing. Not an FDA-approved finished product. Document clinical need over an approved alternative. |
| Oxytocin, glutathione | Conditional | Compoundable. Confirm the pharmacy holds current certificates of analysis. |
| GHK-Cu (copper peptide) | Conditional | Topical use only, with limitations. Injectable routes are not compoundable. The route is the entire question. |
| Compounded semaglutide or tirzepatide | Conditional | Both shortages have ended. A 503A pharmacy may compound only for an individual patient with a documented clinical need the approved product cannot meet. This is not a program offering. |
| Compounded liraglutide | Conditional | Liraglutide injection remains on the shortage list, so 503B compounding is currently available to it. This is the one live exception. Re-verify shortage status before relying on it. |
| BPC-157, TB-500 | Not on the List | Left Category 2 in April 2026. An advisory committee recommended both in July 2026, against FDA staff recommendation. Advisory and non-binding. Neither is on the Bulks List, so neither is lawful to compound. Note that the FDA reviewed BPC-157 for ulcerative colitis, not musculoskeletal repair. |
| KPV, MOTS-c, Semax, Epitalon | Not on the List | Same July 2026 advisory recommendation, same status. Recommended is not listed. |
| Emideltide (DSIP) | Not on the List | The one compound of the seven that the committee declined to recommend. |
| CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, Selank | Not on the List | Left Category 2 in September 2024 when the nominators withdrew their nominations. Never added to Category 1. No Bulks List entry means no lawful 503A compounding. |
| Melanotan II, injectable GHK-Cu, PEG-MGF, ibutamoren, kisspeptin-10, dihexa, LL-37 | Not on the List | Remain restricted. Not compoundable. |
| Anything sold Research Use Only | Not on the List | RUO product is never lawful to administer to a patient, regardless of any category status, and exposes the prescriber to board discipline and FDA action. |
Current as of August 2026. Peptide compounding status has changed four times in the last twenty-four months, so treat every line above as last-known position rather than settled law. Verify against the FDA bulk drug substances pages, your compounding pharmacy of record, and your state board before any clinical or commercial decision. This page is published by a business consulting firm. It is not legal, medical, or regulatory advice and does not create a provider or attorney relationship.
What a Compliant Peptide Clinic Actually Offers
Build on what is lawful today, and treat the rest as a watch list. This menu is narrower than what most competitors advertise. That is the point. It is also the menu that survives an inspection.
FDA-approved GLP-1 agents prescribed as approved products. The highest-demand service line in cash-pay health and the one with the cleanest regulatory footing. See our Metabolic and Weight Loss model.
Sermorelin, prescriber-directed, with documented clinical need over an approved alternative. The defensible core of a growth hormone program, and it pairs naturally with hormone optimization.
PT-141 as the approved finished product, alongside shockwave and other established modalities. See our Sexual Wellness clinic page for the standalone model.
PRP and bone marrow concentrate prepared and returned to the same patient in a single procedure. A different regulatory posture entirely, and the most common redirect when a patient asks for a compound you cannot lawfully offer. See Joint and Musculoskeletal.
Topical GHK-Cu within its limitations, glutathione, and compounded agents your pharmacy can document. Route and documentation decide compliance here, not the compound name.
BPC-157, TB-500, ipamorelin, CJC-1295 and the rest stay on a tracked watch list, not on the menu. If rulemaking publishes, ACG clients add them in weeks because the clinic infrastructure is already built.
How ACG Structures a Defensible Peptide Clinic
The 503A compounding framework, the bulk drug substances lists, state-by-state prescribing variation, and the Medical Director relationship all have to be settled before the first patient.
Paid advertising for this category is restricted on every major platform, so organic search is the durable acquisition channel. ACG builds that infrastructure as part of the setup. Marketing execution is available as a separate engagement.
We would rather hand you a shorter menu you can defend than a longer one you cannot. Every consultant in this category will tell you what is possible. Ask them what is listed.
Every proposed service line is checked against the Bulks List before it reaches a pro forma. Nothing gets priced that cannot be made.
A compliant 503A or 503B partner will tell you plainly what it can and cannot make. ACG connects clients to pre-vetted pharmacies and sits in that conversation with you.
Prescribing authority, oversight requirements, and scope of practice vary by state. ACG introduces clients to vetted physicians across all 50 states and maps the requirements for yours.
Copy that promises what a compound does for a condition can change how that compound is treated. Your website is part of your compliance posture, which is why ACG's marketing audit reviews it.
This category has changed four times in twenty-four months. ACG clients get the current position before a number or a claim goes into a client document.
Why These Patients Become Long-Term Clients
Protocols in this category commonly run 3 to 12 months. Patients who see results stay and refer. The clinic that earns trust here does not compete on price, it competes on outcomes and relationship.
One fee. One engagement. Everything included. No upsells, no ongoing royalties, no franchise dependency. You own the clinic, the brand, and the equity.
3-12 Months
Per patient per protocol, supporting recurring revenue rather than one-off visits.
Independent MD
No medical background is required to own the business. An independent, state-licensed Medical Director directs all clinical care.
Launched
Across all 50 states, over 30+ years of combined operational history.
Launch Window
From keys received, market and regulatory conditions permitting.
Answers Before
You Open.
Straight answers on what is lawful, what is not, and how to build a peptide clinic that holds up. Including the answers that cost us business.
If something isn't covered here, that's what the consultation is for. No pressure, no pitch.
View All FAQsIs BPC-157 legal to prescribe right now?
What is the 503A Bulks List and why does it decide everything?
A peptide came off Category 2. Doesn't that make it legal?
Which peptides can a pharmacy actually make today?
Can I still build a real business on the compliant list?
What is the actual risk if I offer a non-listed compound anyway?
Do I need to be a physician to operate a peptide therapy clinic?
Can I advertise peptide therapy on Meta and Google?
What revenue per patient is realistic in this category?
Build the Clinic That
Survives the Rulemaking.
Book a free 30-minute strategy call. ACG will walk you through the peptide opportunity in your specific market, which service lines are defensible today, the pharmacy picture, and what the process looks like from first conversation to open doors.
Book a Strategy CallFree 30-minute call · No pitch · ACG works with a select number of clients at any given time
Structured to keep you on the right side of the line.
Regenerative health is one of the most heavily scrutinized spaces in medicine. Knowing the rules is not a footnote to what we do. It is the foundation. Here is how we structure every clinic we help launch.
Your Medical Director Directs Care
You own and operate the business. Every clinical, prescribing, and treatment decision is made by an independent, state-licensed Medical Director, structured to respect Corporate Practice of Medicine laws in your state. We connect you to a vetted network; you retain your own provider.
We Know the Regulatory Lines
PRP, peptides, GLP-1 medications, and cellular products each carry their own federal and state rules, and not every product or use is FDA-approved. Some, like exosomes for therapeutic use, are not FDA-approved at all, and we steer you away from them. We help you build a treatment menu on defensible, compliant options and a marketing approach that holds up to FDA, FTC, and state medical board scrutiny.
No Hype. No Guarantees.
We show you real ranges, not fantasy numbers, and we never promise an income or a clinical outcome. What you earn depends on your market, your capital, and your execution. We would rather set honest expectations than sell you a dream.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe, or sell any drug, biologic, device, or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the regulatory compliance of every product, therapy, and claim. See our full regulatory notice below.